se gb

NeoDynamics innovative cancer treatment featured on US news channel

STOCKHOLM - October 6, 2011. The US news channel ABC 7 recently featured NeoDynamics’ innovative and cost-effective treatment of breast cancer. The concept has been proved simple and reliable and a first clinical study with excellent results has been conducted at Capio St. Görans and Danderyds Hospital in Stockholm where 58 patients have been treated. NeoDynamics is partly owned by Karolinska Development.

With combined knowledge and experience in both medical engineering and clinical practice, NeoDynamics has developed a novel method to treat breast cancer in a revolutionary cost-effective way. This patented minimally-invasive technique uses radiofrequency energy (Preferential Radio Frequency Ablation, PRFA) to heat up tumor tissue locally and eliminate cancer cells. It is designated to treat both benign and malignant tumors at an early stage when they have not evolved beyond the size of a walnut. The procedure is carried out under local anaesthesia only.

Furthermore, NeoDynamics' research has shown that this treatment preferentially targets cancerous cells, resulting in the ability to treat tumor strands while leaving healthy fatty tissue unaffected and at the same time prevent spreading of cancer cells (anti-seeding) in the blood stream.

For the full ABC 7 feature, please visit:

For a comprehensive interview with the inventor Prof Hans Wiksell, please visit:

For further information, please contact:
Peter Sellei, M.D., CEO. Mobile: +46 (0)70 624 21 89
Prof. Hans Wiksell, Head of R&D. Mobile +46 (0)70 564 40 30


About Neodynamics
NeoDynamics is a Swedish medical technology company developing equipment to diagnose and treat breast cancer on the same day. The company's technologies for diagnosis and treatment are currently undergoing clinical trials. NeoDynamics' goal is to develop further prototypes for clinical use and enter partnerships that ensure commercialisation and global expansion.

About Karolinska Development
Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class research into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP these to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out licensing of products. This will result in upfront payments, milestone payments and royalties.

An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations.

Karolinska Development's flexible exit strategy enables projects to be exited at whichever stage of development offers the greatest return on investment, usually after Phase II clinical trials have indicated the desired pharmaceutical effect on patients - this being an important value enhancing step.

Today, the portfolio consists of over 35 projects at various stages, from concept development to Phase II clinical trials, twelve projects are in clinical trials. The portfolio is particularly strong in the areas of cancer, dermatology, inflammation, cardiovascular disease, women's health and diseases that affect the central nervous system.

pdf.png NeoDynamics innovative cancer treatment featured on US news channel